[Enlarged mediastinal lymph nodes of a patient with malignant melanoma stage IV under pembrolizumab treatment].
Mediastinale Lymphknotenvergrößerung bei einer Patientin mit malignem Melanom Stadium IV unter Therapie mit Pembrolizumab.
Antibody therapy
Oncological immunotherapy
Sarcoid-like
Sarcoidosis
Systemic steroids
Journal
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
ISSN: 1432-1173
Titre abrégé: Hautarzt
Pays: Germany
ID NLM: 0372755
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
pubmed:
20
3
2019
medline:
7
8
2019
entrez:
20
3
2019
Statut:
ppublish
Résumé
A 40-year-old patient with malignant melanoma pT4bN0M1a stage IV (AJCC classification 2017) was treated with the PD-1/PD-L1 antibody pembrolizumab. Three months after treatment initiation the patient developed enlarged mediastinal lymph nodes despite the partial response of the cutaneous metastases. An elective lymph node extirpation was performed. The histopathological result was consistent with a sarcoid-like reaction. Treatment was discontinued and a pulse therapy with systemic steroids led to a significant remission of the lymphadenopathy. This side effect can manifest both during PD-1/PD-L1 antibody and CTLA-4 antibody therapy and should be included in the differential diagnosis of mediastinal lymphadenopathy.
Identifiants
pubmed: 30887079
doi: 10.1007/s00105-019-4392-x
pii: 10.1007/s00105-019-4392-x
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Steroids
0
pembrolizumab
DPT0O3T46P
Types de publication
Case Reports
Journal Article
Langues
ger
Pagination
443-446Références
Int J Immunopathol Pharmacol. 2014 Jul-Sep;27(3):321-30
pubmed: 25280023
J Clin Oncol. 2015 Oct 1;33(28):3193-8
pubmed: 26282644
Ann Oncol. 2016 Jun;27(6):1178-9
pubmed: 27091806
Chest. 2016 May;149(5):e133-6
pubmed: 27157227
Br J Dermatol. 2017 Apr;176(4):1060-1063
pubmed: 27291635
JAAD Case Rep. 2016 Jul 27;2(4):290-3
pubmed: 27504482
Dtsch Arztebl Int. 2016 Aug 22;113(33-34):565-74
pubmed: 27598883
J Immunother Cancer. 2016 Dec 20;4:94
pubmed: 28031822
Int J Rheum Dis. 2017 Sep;20(9):1277-1285
pubmed: 28480561
J Immunother. 2017 Oct;40(8):307-311
pubmed: 28737620
Rev Med Interne. 2018 Feb;39(2):130-133
pubmed: 29277453
Am J Dermatopathol. 2018 Jul;40(7):523-526
pubmed: 29924748